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60 Poster Session Iregimens. With a median follow-up of 15 months from relapse (0.5–
52), 12 pts are alive, 9 in remission. The most important predicting
factor for survival after relapse was the duration of remission. Pts re-
lapsing . 6 months and\ 6 months after SCT had a median sur-
vival of 7.2 and 1.4 months and estimated 2-year survival of 22%
and 2%, respectively (p \ 0.001). Survival rates were 20%, 0%
and 4% after BuCy, FB2 and FB4, respectively (p 5 0.04). SCT
in refractory disease was also predictive of poor outcome after re-
lapse (p\0.001). Multivariable analysis determined short remission
after SCT and conditioning with FB regimens as independent ad-
verse factors with hazard ratios of 3.3 (1.9–6.3, p\ 0.001) and 2.0
(1.0–4.0, p 5 0.04), respectively. In conclusion the notion that pts
given RIC can be salvaged more easily if they relapse is not substan-
tiated and should not be a rationale to select RIC over myeloablative
conditioning.159
FEASIBILITY OF CLOFARABINE CYTOREDUCTION BEFORE INITIATION
OF ALLOGENEIC STEM CELL TRANSPLANT REGIMEN DURING THE CY-
TOPENIC PHASE FOR PATIENTS WITH REFRACTORY ACUTE MYELOGE-
NOUS LEUKEMIA
Locke, F.L., Artz, A.S., Rich, E.S., van Besien, K., Stock, W. The Uni-
versity of Chicago, Chicago, IL.
Patients with refractory leukemia entering allogeneic stem cell
transplant (Allo-SCT) fare poorly, and higher disease burden corre-
lates with decreased disease free survival (DFS) (van Besien, JCO
2005). To determine the feasibility of clofarabine (CLO) cytoreduc-
tive therapy as a bridge to Allo-SCT we retrospectively analyzed 14
heavily pretreated refractory acute myelogenous leukemia (AML)
pts. All pts received CLO 30–40 mg/m2 intravenous daily for five
consecutive days as bridging therapy with the intention to initiate
Allo-SCT conditioning during the cytopenic phase, 14–21 days
later. Pts had a mean of 2.2 prior treatment regimens, and 8 had pri-
mary refractory leukemia. 4 pts were relapsed following a prior stem
cell transplant (1 autologous and 3 Allo-SCT).
To assess CLO cytoreduction, bone marrow (BM) biopsy and as-
pirate were performed at the nadir, day 12 after CLO. Cytoreduc-
tion was defined as post CLO marrow with\20% cellularity and
\10% blasts. CLO achieved cytoreduction in 8/14 pts. The median
BM cellularity was 45% (4–90%) before and 5% (1–83%) after
CLO. The median BM blast % was 23% (10%-100%) before and
6% (0%-90%) after CLO.
Of the 14 pts, 13 proceeded to Allo-SCT by day 26 (median 22,
range 17–26). 7 pts received a fludarabine, busulfan, campath regi-
men; 5 pts received fludarabine, melphalan with either ATG (2) or
Campath (3); 1 pt received a TBI-based regimen. Grade 4 hyperbi-
lirubinemia prevented one pt from proceeding to Allo-SCT prepar-
ative regimen.
Of the 13 pts receiving Allo-SCT the median follow up is 15
months for survivors. 3 pts are alive and disease free at 4.3, 16.5,
and 40 months after Allo-SCT, and all achieved CLO cytoreduc-
tion. 2 pts are alive with progressive disease at 8 and 15 months.
The overall DFS at day 100 was 9/13. 3 pts relapsed before day
100, 2 of whom did not achieve cytoreduction. Beyond day 100
an additional 3 pts relapsed at 5.5, 5.5, and 6.5 months. 1 pt died
of treatment related motality (TRM), sepsis, at day 17. The TRM
at day 100 was 1/13, and 4/13 at one year.
In conclusion, 13/14 patients with refractory AML were able to
undergo Allo-SCT with acceptable TRM in this heavily pretreated
group after CLO re-induction. Based on these data, we are pursuing
a prospective feasibility study of CLO cytoreduction followed by
Allo-SCT during the cytopenic phase.160
PLASMA AND CSF PHAMACOKINETICS (PK) AND RESPONSE TO DASATI-
NIB IN A YOUNG CHILDWITH RELAPSING Ph1 ALL AFTER ALLOGENEIC
TRANSPLANT
Morris, C.L.1, Brown, W.C.2, Zappia, J.3, Morris, J.1 1Loma Linda
University Medical Center, Loma Linda, CA; 2Loma Linda University
Medical Center, Loma Linda, CA; 3Loma Linda University Medical
Center, Loma Linda, CA.Background: Dasatinib is a second-generation abl tyrosine ki-
nase inhibitor approved for patients with imatinib-intolerant or re-
sistant CML and Ph1 ALL. Plasma PK has not been studied in
children or CSF.Methods: Prospective analysis of dasatinib plasma
and CSF levels and clinical response in an 8-year-old male with Ph1
ALL in relapse (diagnosed at age 6 y). Serum and CSF levels were
determined by liquid chromatography tandem mass spectrometry
with a detection limit of 1 ng/ml. Results: The patient received
an unrelated donor stem cell transplant in 1st remission and a second
transplant following relapse 6 mo later. He received Imatinib 300
mg po QD (15 mg/kg) during consolidation, maintenance, and fol-
lowing his 1st transplant. He developed headache, leg pain, and a sin-
gle skin nodule of leukemia 7 mo after his last transplant. CSF had 7
blasts/ul, head CT showed hyper-intense chloromas in frontal, pa-
rietal, and temporal lobes, and a right ileopsoas mass. Bone marrow
was in remission, peripheral blood had 0.15% BCR/ABL by RT-
PCR. Dasatinib 40 mg po bid (1.5 mg/kg) was started. No other
chemotherapy was given. Clinical symptoms resolved after 6 days.
After 9 the CNS lesions became hypointense. Two large frontal
lobe masses, 1 parenchymal and 1 extra-axial, decreased in volume
from15 cc to 1.1 cc and CSF blasts to\1/ul. By day 23 the chlor-
omas had nearly resolved and CSF blasts were 0 by day 34. The
psoas mass resolved after 14 d. Plasma PK was measured 3 times,
and CSF 6 times at various points after dose. CNS response varied
with plasma level. Plasma levels after 7 d on 40 mg bid were slightly
lower than expected from adult data, (AUC 146 ng-h/ml, Cmax
40.4 ng-h/ml, and T1/2 2.2 hours). CSF levels were not detected
at any time point. On day 171 the patient developed disseminated
adenovirus and died on day 178. Post mortem showed no leukemia
in blood, marrow, or psoas muscle tissue by RT-PCR. There was
microscopic perivascular leukemia cell infiltration in the frontal
lobe, thalamus, and cerebellum. There was no evidence of CNS in-
fection. Conclusions: In this child plasma PK was similar to results
in adults. Ph1 leukemia in the CNS may respond to dasatinib de-
spite very low drug levels in the CSF.161
SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
FOR ACUTE LEUKEMIAS RELAPSING AFTER FIRST TRANSPLANT IN PE-
DIATRIC PATIENTS
Martinez, C., Verneris, M.R., Weigel, B.J., Kumar, A., Baker, K.S.
University of Minnesota, Minneapolis, MN.
Recurrent leukemia is the most frequent indication for second al-
logeneic hematopoietic cell transplantation (HCT) in pediatric pa-
tients. However, there are few reports describing in detail the
overall survival in children who undergo a second stem cell trans-
plant procedure. We present our experience from the University
of Minnesota describing the outcome of 23 patients with either
acute lymphoblastic leukemia (ALL, n5 9) or acute myeloid leuke-
mia/myelodysplastic syndrome (AML/MDS, n 5 14) who had re-
lapsed after a first HCT and received a second allogeneic
transplant. The median age at the time of second transplant was
10 yrs for the AML/MDS patients and 6.8 yrs for the ALL patients.
All of the ALL patients were in complete remission at time of sec-
ond transplant, for the AML/MDS patients 6 were in remission
and 8 had active leukemia at the time of second HCT. The mean
time from first transplant to relapse for the ALL group was 406
days (range 0–729) and 619 days (range 20–4410) for the AML/
MDS group. Five patients received a second HCT from the same
donor source, 6 patients who had prior autologous HCT received
an unrelated donor (n5 5) or related donor (n5 1) for their second
HCT, and the remaining patients (n5 12) received a different allo-
geneic stem cell source. All of the patients except one patient with
AML/MDS received myeloablative conditioning with the second
HCT. Patients who received TBI with the first HCT were treated
with chemotherapy only conditioning regimens and those who had
not received TBI with the first HCT were treated with TBI based
regimens for the second HCT. The mean follow-up of the patients
with AML/MDS was 543 days (range 72–2109) and 708 days (range
23–2064) for the ALL group. The overall survival was 30% (n5 7),
four of fourteen survived in the AML/MDS group and three of nine
in the ALL group. Among the survivors the mean time from first
Poster Session I 61transplant to relapse was 466 days (range 182–729) for the ALL
group, and 2270 days (range 130–4410) for the AML/MDS group.
The primary cause of death was disease recurrence (n 5 11), three
ALL and eight AML/MDS patients. Three patients died of acute
GVHD, 2 from infection, and for one AML/MDS patient a specific
cause of death was not known. These data show that even when re-
lapse after a first HCT occurs, nearly 1/3 of pediatric patients with
acute leukemia may still be salvaged with a second HCT.162
EVALUATION OF A POWERED INTRAOSSEOUS DEVICE FOR BONE MAR-
ROW SAMPLING
Cohen, S.C., Soroka, J.M. Cancer Care Center of South Texas, San An-
tonio, TX.
The importance of bone marrow examination in the evaluation of
leukemia, multiple myeloma, anemia, pancytopenia, and other dis-
orders is well established. The objective for this study was to evalu-
ate the ability of a powered bone marrow aspiration device to
penetrate the intraosseous medullary space of the iliac crest, and
to aspirate bone marrow samples for the ultimate purpose of diag-
nosing disease and monitoring the course of disease and medical
therapy. The device was used to obtain bone marrow samples in ac-
cordance with accepted practice guidelines and device’s directions
for use. Among other data, insertion success, time to insertion,
and complications were recorded. Patient pain levels were rated
from 0 to 10 (105extreme pain). Device operators rated the use
of the device from 0 to 10 (105outstanding). There were 55 patients
in the study from three centers. Successful insertion and aspiration
of bone marrow samples were achieved in 54 of the 55 patients
(98.1%). Mean insertion time was 4.9 6 3.0 seconds; significantly
faster than the 7.3 minutes reported by Kuball et al* (one-sample
t-test, p\ 0.001). There were no complications. The mean inser-
tion pain score was 2.5 6 2.2 and the mean aspiration pain score
was 3.7 6 2.5. On a scale of 0 to 10, the six operators rated the
ease of use of the device at a mean score of 8.36 1.7. Findings sug-
gest that the powered aspiration device is safe and effective for bone
marrow aspirations; and that through the use of powered device,
needle placement time can be reduced—thereby reducing patient
pain.
* Kuball J, Schu¨z J, Gamm H, Weber M. Bone marrow punctures
and pain. Acute Pain 2004;6(1):9–14.163
CLOFARABINE PRE-CONDITIONING PRIOR TO ALLOGENEIC STEM CELL
TRANSPLANTATION IN HIGH RISK ACUTE MYELOID LEUKAEMIA (AML):
A WELL TOLERATED REGIMEN WITH BOTH FULL AND REDUCED TOX-
ICITY SCHEDULES
Richardson, D.S., Hurlock, C., Hill, K., Newman, J., McKeag, N.,
Groves, L., Orchard, K.H. Southampton University Hospitals, South-
ampton, Hampshire, United Kingdom.
The outcome for patients with high-risk AML, particularly those
with leukaemia at the time of allogeneic transplant remains poor
even using full intensity conditioning. A recently published ap-
proach used pre-conditioning chemotherapy prior to the delivery
of a reduced intensity transplant schedule during the period of cyto-
penia. Initial results indicate feasibility and potential for long-term
disease control.
The bi-halogen purine analogue Clofarabine has significant ac-
tivity as a single agent in AML and is well tolerated. These charac-
teristics suggest Clofarabine is an ideal agent to use as pre-
conditioning therapy.
We have treated 5 patients with high-risk, refractory AML using
Clofarabine pre-conditioning to reduce disease burden before full
or reduced intensity allogeneic transplantation. In 4 patients, Clo-
farabine was administered as a single agent (40 mg/m2/day for 5
days) and in one, in combination with Cytarabine. 2 received re-
duced toxicity Busulphan-containing transplant schedules; 3 re-
ceived full intensity, TBI-based conditioning. The indications for
using Clofarabine in these patients, included severe allergy to Cy-
tarabine and heavy prior exposure to anthracycline. All 5 patientshad marrow involvement with AML prior to administration of Clo-
farabine. No unexpected toxicity was encountered and the extended
period of cytopenia compared with a conventional transplant was
manageable in this cohort. One patient who received a reduced in-
tensity regimen, was treated for VOD on the basis of clinical suspi-
cion but liver biopsy showed evidence of grade 3–4 haemosiderosis
only. 2 patients who received TBI suffered grade 3–4 mucositis and
required parenteral nutrition. All patients achieved .98% donor
chimerism at day 130. No patient experienced grade 3–4 acute
GvHD. 4 of 5 patients achieved substantial bulk reduction or erad-
ication of marrow AML infiltration following Clofarabine. The pa-
tient with Clofarabine-refractory disease achieved CR at day 30
following a full intensity transplant but has relapsed at 4 months
post transplant. One patient died in CR at 5 months post transplant
from pneumonitis. 3 patients are currently in CR at 2.5–21 months
follow up. The use of Clofarabine as a pre-conditioning agent prior
to the administration of the transplant conditioning schedule is well
tolerated with both full and reduced intensity protocols. This ap-
proach to allogeneic transplantation shows promise for the therapy
of patients with high risk, refractory AML.164
CLINICAL FEATURES OF ACUTE LEUKEMIA WITH CO-EXPRESSION OF
MYELOID AND LYMPHOID ANTIGENS
Jeong, S.H.1, Lee, H.W.1, Kang, S.Y.1, Cho, S.R.2, Park, J.S.1,
Choi, J.H.1, Kim, H.C.1 1Ajou University School of Medicine, Suwon,
Kyeong-Ki Do, Korea; 2Ajou University School of Medicine, Suwon,
Kyeong-Ki Do, Korea.
Background: Treatment of acute leukemias coexpressing mye-
loid and lymphoid antigens but does not meet the criteria for biphe-
notypic acute leukemia by EGIL is uncertain and its prognosis
unpredictable. We studied clinical outcomes of those acute leuke-
mia with coexpression. Method: Medical charts from 68 patients
diagnosed as coexpressing acute leukemia between Jan. 2000 and
Dec. 2006 in Ajou University Hospital were reviewed retrospec-
tively. 17/52 AML patients and 5/16 ALL patients received Hema-
topoietic stem cell transplantation. Significance was obtained by
two-tailed Student’s t-test and survival analyzed by Kaplan-Meier
method. Results: The median age for all acute leukemia was 42.5
year (15  83). Age, gender, LDH level and cytogenetics were
not different compared to those diagnosed as single lineage acute
leukemia at the same time. Forty eight % (16/33) of ALL and
30% (52/176) of AML patients co-expressed counterpart lineage
markers. CD19 (11%), CD7 (10%), CD22 (8%), CD5 (8%),
CD10 (1%) in AML and CD13 (42%), CD33 (33%), CD14 (3%)
in ALL were co-expressed. The co-expressed AML patients showed
tendency to short survival duration compared with pure AML pa-
tients (18.5 months vs. 24.1 months, p 5 0.069). Co-expressed
AML patients without stem cell transplantation showed shorter sur-
vival than pure AML patients (12.9 months vs. 21 months, p 5
0.014). However in AML who were transplanted, the survival ad-
vantage was abrogated (coexpressed vs pure AML; 30 months vs.
35 months, p 5 0.244). In ALL, survival duration of the co-ex-
pressed patients was not shorter than that of pure ALL (19.4 months
vs. 21 months) regardless of transplantation. Conclusion: AML pa-
tients with co-expression of lymphoid markers should be regarded
as a poor prognostic group and more aggressive treatment such as
transplantation should be considered. Further study on a larger
number of patients should be investigated regarding the appropriate
criteria for BAL and treatment.165
CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT AT DIAGNOSIS DOES
NOT ADVERSELY AFFECT THE OUTCOME OF HIGH-DOSE CHEMOTHER-
APY AND TRANSPLANT FOR PATIENTS WITH ACUTE MYELOID LEUKE-
MIA (AML)
Petropoulos, D.1, Giralt, S.A.2, Andersson, B.S.2, Chan, K.W.3,
Rondon, G.2, Popat, U.R.2, Hosing, C.2, Alousi, A.M.2,
Champlin, R.E.2, de Lima, M.J.2 1MD Anderson Cancer Center,
